Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 June 2020Americas

PTAB to review Minnesota patent after Gilead petition

Gilead Sciences has persuaded the US Patent Trial and Appeal Board (PTAB) to review an antiviral patent owned by the  University of Minnesota (UM).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

More on this story

Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?